Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University College London

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

In Memory

Changing healthcare, one film at a time

Successfully marrying educational content with an entertaining format can help to truly maximise audience engagement

Bedrock Healthcare Communications

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

Detecting Alzheimer’s ahead of a cure

A focus on promising new research

- PMLiVE

A roadmap to the successful treatment of Alzheimer’s disease

Building on past research to learn more about the disease and how to treat it

What is changing in mental health and dementia care?

Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services

Wilmington Healthcare

- PMLiVE

Acadia’s drive to extend use of Nuplazid hits a wall

Shares in company down

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links